Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 250.83M P/E - EPS this Y 31.00% Ern Qtrly Grth -
Income -93.24M Forward P/E -4.00 EPS next Y -6.00% 50D Avg Chg -10.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book 2.16 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.60 Quick Ratio 21.67 Shares Outstanding 56.43M 52W Low Chg 113.00%
Insider Own 0.47% ROA -20.04% Shares Float 34.22M Beta 0.72
Inst Own 98.95% ROE -34.06% Shares Shorted/Prior 3.82M/3.95M Price 8.95
Gross Margin - Profit Margin - Avg. Volume 256,843 Target Price 25.14
Oper. Margin - Earnings Date Nov 11 Volume 217,717 Change 3.59%
About Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Astria Therapeutics, Inc. News
11/13/24 Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
11/13/24 Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
11/04/24 Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/30/24 Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
07:00 AM Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
10/18/24 Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
10/16/24 European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
09/30/24 Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
09/27/24 Astria Therapeutics to Present at Upcoming Global Angioedema Forum
09/19/24 Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
08/30/24 Astria Therapeutics to Present at Upcoming Bradykinin Symposium
08/29/24 Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
08/12/24 Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
08/12/24 Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
08/07/24 Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
05/30/24 Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
05/24/24 Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
05/23/24 Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
05/11/24 We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
05/09/24 Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
ATXS Chatroom

User Image PenkeTrading Posted - 2 days ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Astria Therapeutics Inc. Is that bullish or bearish? $ATXS #Astria #RsiOversold #NASDAQ

User Image Elisabeth0Mercado Posted - 6 days ago

$YMAB $ATXS MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏

User Image Thestocktraderhubzee Posted - 6 days ago

WATCHLIST NOV 15 2024.. $ATXS HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target $CSCO Citigroup Maintains Buy on Cisco Systems, Raises Price Target to $64 $XFOR HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5 $SNCY Barclays Maintains Overweight on Sun Country Airlines, Raises Price Target to $24 $JBLU Barclays Maintains Underweight on JetBlue Airways, Raises Price Target to $7

User Image ChessGM Posted - 2 weeks ago

$ATXS Heads up alert! Upcoming earnings on Monday, 11/11/2024 for $ATXS Neutral (5.5) In reviewing the recent developments surrounding Astria Therapeutics, Inc. (Nasdaq: ATXS), the company appears to be navigating a critical phase in its growth trajectory. Key financial metrics indicate that while the firm remains in the early stages of its product pipeline, it is making significant strides in securing regulatory designations and preparing for upcoming presentations that could enhance its visibility in the biopharmaceutical landscape. The stock currently trades with a P/E ratio that suggests it is not yet generating profits, typical for companies in its phase. However, the anticipation surrounding navenibart's Orphan Drug Designation and European Commission's OMPD could drive investor interest. Analysts project a substantial increase in EPS as clinical results from ongoing trials, such as the ALPHA-STAR trial, are expected to be released, which may provide insights into the drug's efficacy and market potential. Revenue forecasts remain speculative but optimistic, contingent upon successful trial outcomes and subsequent approvals. Looking ahead, the upcoming earnings report is expected to highlight the company's progress in clinical trials and any advancements in regulatory approvals. Historical performance indicates that Astria has maintained a steady pace in its development pipeline, with the consensus estimate for this quarter leaning towards a loss per share, in line with previous quarters. Analysts anticipate that the focus will be on updates regarding navenibart’s clinical efficacy and strategic partnerships that could bolster its market position. As such, the stock's performance may hinge on the sentiment generated by these developments, with analysts closely monitoring the interim results to gauge investor confidence moving forward. The consensus forecasts suggest a cautious optimism, but any significant deviation from expected outcomes could lead to volatility in the stock's valuation. - Funds were net buyers of $ATXS during the previous reporting quarter. - Top 5 funds with large holdings in $ATXS: * Perceptive Advisors LLC $59MM. New position. CGMFundRank: 57%, Fund Website: www.perceptivelife.com * RA Capital Management LLC $46MM. New position. CGMFundRank: 61%, Fund Website: www.racap.com * Adage Capital P $7MM. New position. CGMFundRank: 87%, Fund Website: www.adagecapital.com * Nantahala Capital Management LLC $6MM. New position. CGMFundRank: 70%, Fund Website: www.nantahalapartners.com * Sio Capital Management LLC $5MM. New position. CGMFundRank: 56%, Fund Website: www.siocapital.com - Last 10 days performance: -2% - Last 30 days performance: 6% - Last 90 days performance: 25% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.

User Image Shlobby Posted - 10/24/24

$ATXS

User Image Shlobby Posted - 10/24/24

$ATXS getting tight

User Image S_Franconi Posted - 1 month ago

$ATXS Presentation Detail. https://ir.astriatx.com/news-releases/news-release-details/astria-therapeutics-present-upcoming-american-college-allergy

User Image S_Franconi Posted - 1 month ago

$ATXS Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting Oct 25th

User Image S_Franconi Posted - 1 month ago

$ATXS @G101SPM Can you run this one?

User Image briefingcom Posted - 1 month ago

$ATXS: Astria Therapeutics announces that the European Commission has granted Orphan Medicinal Product Designation to navenibart for the treatment of hereditary angioedema https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241016080841ATXS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Doozio Posted - 1 month ago

$ATXS 🍿. Mmmmkay bahhhhdy!! At least a 🧠👀 is da FUTUre of 🧠⏰ which is NOW during 🧠⏰♾️

User Image therealinvestor Posted - 09/26/24

$ATXS Huge bull flag on the daily. Hmm…

User Image Botanical_Brian Posted - 09/25/24

$ATXS out starting @ 11.20 down to 10.90 +$6,137.45 thx for the chips

User Image Botanical_Brian Posted - 09/25/24

$ATXS shorted 9,000 shares this am with avg cost $11.77

User Image theboss1 Posted - 09/24/24

$ATXS is this anything? Or just insignificant share move?!

User Image BioRich Posted - 2 months ago

$ATXS

User Image PenkeTrading Posted - 2 months ago

I found you a Morning Star Candle Pattern on the daily chart of Astria Therapeutics Inc. $ATXS #Astria #MorningStar #NASDAQ

User Image Stock_Titan Posted - 3 months ago

$ATXS Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update https://www.stocktitan.net/news/ATXS/astria-therapeutics-reports-second-quarter-2024-financial-results-b23l4k3jlmhk.html

User Image Stock_Titan Posted - 3 months ago

$ATXS Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema https://www.stocktitan.net/news/ATXS/astria-therapeutics-chooses-ypsomed-s-ypso-mate-as-the-injection-xa0ghxrlt6vb.html

User Image NVDAMillionaire Posted - 07/30/24

$ATXS Astria Therapeutics, Inc. (ATXS): A Promising Biopharmaceutical Company Advancing Novel Therapies for Allergic and Immunological Diseases http://beyondspx.com/2024/07/30/astria-therapeutics-inc-atxs-a-promising-biopharmaceutical-company-advancing-novel-therapies-for-allergic-and-immunological-diseases/

User Image MarkettMaven Posted - 4 months ago

$MAXN $RMBL $ATXS ⭐️Top gainers on our yesterday’s watchlist. 👉🏼Follow us to never miss on the next big move.

User Image HeadRush Posted - 4 months ago

$ATXS Good news inbound?

User Image Lord_Monsoon Posted - 4 months ago

$ATXS do we have some news driving the price back up?

User Image TickerDD_com Posted - 4 months ago

From 6/14/2024, looking back across 21 Month-Ends for ATXS, Percentage Change of Average Monthly Price had More Positives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $ATXS #ATXS #ATXSStock #TickerDD #ATXSPrice https://www.youtube.com/watch?v=-Qeaa_y3RjI

User Image kubota2323 Posted - 06/24/24

$ATXS adding

User Image AnaChart Posted - 6 months ago

$ATXS https://anachart.com/wp-content/uploads/ana_temp/1716292987_soc-img.jpg

User Image G101SPM Posted - 6 months ago

#SHOWTIME American Thoracic Society Conference (May 16-21) Scheduled to appear: $BIAF,$ KYMR Society for Investigative Dermatology Meeting (May 16-17) Scheduled to appear: $PHIO, $ATXS, $VYNE, $AZTR

User Image Stock_Titan Posted - 6 months ago

$ATXS Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update https://www.stocktitan.net/news/ATXS/astria-therapeutics-reports-first-quarter-2024-financial-results-and-9dj270hi5uwf.html

User Image BillRayValentine Posted - 6 months ago

$ATXS Excellent. Nobody is here yet.! I love it.

User Image BillRayValentine Posted - 6 months ago

$ATXS $9.24 Entry

Analyst Ratings
HC Wainwright & Co. Buy Sep 27, 24
Wedbush Outperform Aug 13, 24
Oppenheimer Outperform Aug 13, 24
HC Wainwright & Co. Buy Aug 13, 24
TD Cowen Buy Jul 29, 24
Oppenheimer Outperform May 21, 24
HC Wainwright & Co. Buy May 10, 24
Wedbush Outperform May 10, 24
HC Wainwright & Co. Buy Apr 23, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PERCEPTIVE ADVISORS LLC Director Director Feb 01 Buy 12.09 2,481,350 29,999,522 4,873,721 02/05/24
Morabito Christopher Chief Medical Office.. Chief Medical Officer Jan 26 Sell 11.08 10,000 110,800 01/30/24
Morabito Christopher Chief Medical Office.. Chief Medical Officer Jan 26 Option 3.87 10,000 38,700 9,200 01/30/24
PERCEPTIVE ADVISORS LLC Director Director Dec 19 Buy 11.01 908,265 9,999,998 1,038,309 12/21/22